Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine whether zoledronic acid (Zometa) given
once annually increases bone mineral density in men receiving hormone therapy for prostate
cancer.